Colesevelam improves oral but not intravenous glucose tolerance by a mechanism independent of insulin sensitivity and β-cell function

Diabetes Care

Volumn 35, Issue 5, 2012, Pages 1119-1125

  Marina, Anna L ^a   Utzschneider, Kristina M ^a   Wright, Lorena A ^a   Montgomery, Brenda K ^a   Marcovina, Santica M ^a   Kahn, Steven E ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLECYSTOKININ; COLESEVELAM; FIBROBLAST GROWTH FACTOR; GASTRIC INHIBITORY POLYPEPTIDE; GASTROINTESTINAL POLYPEPTIDE; GLUCAGON; GLUCAGON LIKE PEPTIDE; GLUCOSE; HEMOGLOBIN A1C; INSULIN; LIPID; PLACEBO; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; AGED; ANTHROPOMETRY; ANTIDIABETIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BODY MASS; CELL FUNCTION; CHOLELITHIASIS; CLINICAL ARTICLE; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET RESTRICTION; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; EVENING DOSAGE; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; IMPAIRED GLUCOSE TOLERANCE; INSULIN SENSITIVITY; INTRAVENOUS GLUCOSE TOLERANCE TEST; MALE; ORAL GLUCOSE TOLERANCE TEST; PANCREAS ISLET BETA CELL; PATIENT COMPLIANCE; SINGLE BLIND PROCEDURE; TREATMENT DURATION;

ADULT; AGED; ALLYLAMINE; BLOOD GLUCOSE; FEMALE; GLUCOSE INTOLERANCE; GLUCOSE TOLERANCE TEST; HUMANS; INSULIN RESISTANCE; INSULIN-SECRETING CELLS; MALE; MIDDLE AGED;

EID: 84862087518     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc11-2050     Document Type: Article

References (30)

1. Zieve FJ, Kalin MF, Schwartz SL, Jones MR, Bailey WL. Results of the glucose-lowering effect of WelChol study (GLOWS): a randomized, double-blind, placebocontrolled pilot study evaluating the effect of colesevelam hydrochloride on glycemic control in subjects with type 2 diabetes. Clin Ther 2007;29:74-83 (Pubitemid 46414026)
2. Fonseca VA, Rosenstock J, Wang AC, Truitt KE, Jones MR. Colesevelam HCl improves glycemic control and reduces LDL cholesterol in patients with inadequately controlled type 2 diabetes on sulfonylurea-based therapy. Diabetes Care 2008;31:1479-1484
3. Bays HE, Goldberg RB, Truitt KE, Jones MR. Colesevelam hydrochloride therapy in patients with type 2 diabetes mellitus treated with metformin: glucose and lipid effects. Arch Intern Med 2008;168:1975-1983
4. Goldberg RB, Fonseca VA, Truitt KE, Jones MR. Efficacy and safety of colesevelam in patients with type 2 diabetes mellitus and inadequate glycemic control receiving insulin-based therapy. Arch Intern Med 2008;168:1531-1540
5. Holt JA, Luo G, Billin AN, et al. Definition of a novel growth factor-dependent signal cascade for the suppression of bile acid biosynthesis. Genes Dev 2003;17:1581-1591 (Pubitemid 36828786)
6. Lefebvre P, Cariou B, Lien F, Kuipers F, Staels B. Role of bile acids and bile acid receptors in metabolic regulation. Physiol Rev 2009;89:147-191
7. Kalaany NY, Mangelsdorf DJ. LXRS and FXR: the yin and yang of cholesterol and fat metabolism. Annu Rev Physiol 2006;68:159-191
8. Mitro N, Mak PA, Vargas L, et al. The nuclear receptor LXR is a glucose sensor. Nature 2007;445:219-223 (Pubitemid 46095727)
9. Laffitte BA, Chao LC, Li J, et al. Activation of liver X receptor improves glucose tolerance through coordinate regulation of glucose metabolism in liver and adipose tissue. Proc Natl Acad Sci U S A 2003;100:5419-5424 (Pubitemid 36542720)
10. Kim TH, Kim H, Park JM, et al. Interrelationship between liver X receptor alpha, sterol regulatory element-binding protein-1c, peroxisome proliferator-activated receptor gamma, and small heterodimer partner in the transcriptional regulation of glucokinase gene expression in liver. J Biol Chem 2009;284:15071-15083
11. Shang Q, Saumoy M, Holst JJ, Salen G, Xu G. Colesevelam improves insulin resistance in a diet-induced obesity (F-DIO) rat model by increasing the release of GLP-1. Am J Physiol Gastrointest Liver Physiol 2010;298:G419-G424
12. Chen L, McNulty J, Anderson D, et al. Cholestyramine reverses hyperglycemia and enhances glucose-stimulated glucagon-like peptide 1 release in Zucker diabetic fatty rats. J Pharmacol Exp Ther 2010;334:164-170
13. Schwartz SL, Lai YL, Xu J, et al. The effect of colesevelam hydrochloride on insulin sensitivity and secretion in patients with type 2 diabetes: a pilot study. Metab Syndr Relat Disord 2010;8:179-188
14. Suzuki T, Oba K, Igari Y, et al. Colestimide lowers plasma glucose levels and increases plasma glucagon-like PEPTIDE-1 (7-36) levels in patients with type 2 diabetes mellitus complicated by hypercholesterolemia. J Nihon Med Sch 2007;74:338-343 (Pubitemid 47523077)
15. Katsuma S, Hirasawa A, Tsujimoto G. Bile acids promote glucagon-like peptide-1 secretion through TGR5 in a murine enteroendocrine cell line STC-1. Biochem Biophys Res Commun 2005;329:386-390 (Pubitemid 40255465)
16. Bergman RN, Ider YZ, Bowden CR, Cobelli C. Quantitative estimation of insulin sensitivity. Am J Physiol 1979;236:E667-E677 (Pubitemid 9220487)
17. Kahn SE, Prigeon RL, McCulloch DK, et al. Quantification of the relationship between insulin sensitivity and beta-cell function in human subjects. Evidence for a hyperbolic function. Diabetes 1993;42:1663-1672 (Pubitemid 23318125)
18. Bardet S, Pasqual C, Maugendre D, Remy JP, Charbonnel B, Sai P. Inter and intra individual variability of acute insulin response during intravenous glucose tolerance tests. Diabete Metab 1989;15:224-232 (Pubitemid 19277468)
19. Chandra R, Liddle RA. Neural and hormonal regulation of pancreatic secretion. Curr Opin Gastroenterol 2009;25:441-446
20. Liddle RA, Rushakoff RJ, Morita ET, Beccaria L, Carter JD, Goldfine ID. Physiological role for cholecystokinin in reducing postprandial hyperglycemia in humans. J Clin Invest 1988;81:1675-1681
21. Odunsi-Shiyanbade ST, Camilleri M, McKinzie S, et al. Effects of chenodeoxycholate and a bile acid sequestrant, colesevelam, on intestinal transit and bowel function. Clin Gastroenterol Hepatol 2010;8:159-165
22. Cheung GW, Kokorovic A, Lam CK, Chari M, Lam TK. Intestinal cholecystokinin controls glucose production through a neuronal network. Cell Metab 2009;10:99-109
23. Kogire M, Gomez G, Uchida T, Ishizuka J, Greeley GH Jr, Thompson JC. Chronic effect of oral cholestyramine, a bile salt sequestrant, and exogenous cholecystokinin on insulin release in rats. Pancreas 1992;7:15-20
24. Koop I, Fellgiebel A, Koop H, Schafmayer A, Arnold R. Effect of cholestyramine on plasma cholecystokinin and pancreatic polypeptide levels, and exocrine pancreatic secretion. Eur J Clin Invest 1988;18:517-523
25. Liddle RA. Regulation of cholecystokinin secretion by intraluminal releasing factors. Am J Physiol 1995;269:G319-G327
26. Koop I, Schindler M, Bosshammer A, Scheibner J, Stange E, Koop H. Physiological control of cholecystokinin release and pancreatic enzyme secretion by intraduodenal bile acids. Gut 1996;39:661-667 (Pubitemid 26426465)
27. Koide M, Okabayashi Y, Otsuki M. Role of endogenous bile on basal and postprandial CCK release in humans. Dig Dis Sci 1993;38:1284-1290 (Pubitemid 23242242)
28. Otsuki M. Pathophysiological role of cholecystokinin in humans. J Gastroenterol Hepatol 2000;15(Suppl.):D71-D83 (Pubitemid 30190729)
29. Garg SK, Ritchie PJ, Moser EG, Snell-Bergeon JK, Freson BJ, Hazenfield RM. Effects of colesevelam on LDL-C, A1c and GLP-1 levels in patients with type 1 diabetes: a pilot randomized double-blind trial. Diabetes Obes Metab 2011;13:137-143
30. Utzschneider KM, Tong J, Montgomery B, et al. The dipeptidyl peptidase-4 inhibitor vildagliptin improves beta-cell function and insulin sensitivity in subjects with impaired fasting glucose. Diabetes Care 2008;31:108-113